Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

1.02

Mkt cap

6.9M

Volume

193K

High

1.09

P/E Ratio

-0.27

52-wk high

4.17

Low

1.00

Div yield

N/A

52-wk low

0.77

In Friday's after-market session, several healthcare stocks experienced significant movements. Talphera (TLPH) led the gainers with a 10.2% increase, while Atreca (BCEL) saw the largest decline among the losers, dropping 9.6%. Other notable gainers included Biora Therapeutics (BIOR), Vanda Pharma (VNDA), Unity Biotechnology (UBX), Adial Pharmaceuticals (ADIL), and Alaunos Therapeutics (TCRT). On the losing side, Windtree Therapeutics (WINT), Fusion Pharmaceuticals (FUSN), Elicio Therapeutics (ELTX), Shattuck Labs (STTK), and Acutus Medical (AFIB) also saw their stock prices fall.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 9:31 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Mesoblast (MESO) saw a 22.1% increase, while Sangamo Therapeutics (SGMO) rose by 20.27%. Telesis Bio (TBIO) and INVO Bioscience (INVO) also saw gains of 19.27% and 17.43%, respectively. Coherus BioSciences (CHRS) and TC BioPharm (TCBP) shares increased as well. On the downside, Esperion Therapeutics (ESPR) fell by 17.7%, Adial Pharmaceuticals (ADIL) by 15.47%, Accelerate Diagnostics (AXDX) by 10.91%, Alaunos Therapeutics (TCRT) by 9.47%, Nuwellis (NUWE) by 9.12%, and MorphoSys (MOR) by 8.7%.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 1:06 pm

Adial Pharmaceuticals has appointed Tony Goodman as its new Chief Operating Officer (COO).

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:31 pm

Adial Pharmaceuticals has received the final reimbursement payment of $350,000 from Adovate. The agreement includes potential development and approval milestones of up to $11 million per compound, with a total of up to $33 million for the first three compounds. Additionally, there are $50 million in commercial milestones, totaling up to $83 million, plus potential payments for additional compounds. Adial also secured a low single-digit royalty and a 15% equity stake in Adovate, with anti-dilution protection to maintain this ownership percentage until Adovate receives $4 million in cumulative funding.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:08 pm

In Thursday's after-market session, several healthcare stocks experienced significant movements. Exicure (XCUR) saw a 54.5% increase, while Avid Bioservices (CDMO) dropped 22.5% following their Q2 earnings release. Other notable gainers included Aligos Therapeutics (ALGS), Tonix Pharmaceuticals (TNXP), Reshape Lifesciences (RSLS), Tharimmune (THAR), and Adial Pharmaceuticals (ADIL). Conversely, Processa Pharma (PCSA), Solid Biosciences (SLDB), Modular Medical (MODD), 89bio (ETNB), and Senti Biosciences (SNTI) were among the losers.

Portfolio Pulse from Benzinga Insights

December 07, 2023 | 9:31 pm

Adial Pharmaceuticals' stock is trading higher following the announcement that the company has regained compliance with a Nasdaq listing requirement.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 9:40 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Adial Pharmaceuticals (ADIL) saw a 30.5% increase in shares to $2.78, while Dyadic International (DYAI) rose by 9.35% to $1.87. AcelRx Pharmaceuticals (ACRX) shares went up by 9.34% to $0.75, Quoin Pharmaceuticals (QNRX) increased by 9.33% to $4.8, and Revelation Biosciences (REVB) rose by 9.2% to $0.8. NexImmune (NEXI) also saw a rise of 9.03% to $1.81. On the losing side, China Pharma Holding (CPHI) shares fell by 10.6% to $0.12, Vivos Therapeutics (VVOS) declined by 9.76% to $37.0, Altamira Therapeutics (CYTO) dropped by 8.23% to $0.59, Kintara Therapeutics (KTRA) decreased by 6.33% to $0.37, Addex Therapeutics (ADXN) fell by 6.2% to $5.3 following their Q3 earnings report, and LumiraDx (LMDX) went down by 5.88% to $0.11.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 9:31 pm

Adial Pharmaceuticals has regained compliance with Nasdaq's listing requirements, likely averting the risk of delisting. This development could restore investor confidence in the company's stock, ADIL, and potentially lead to a positive short-term impact on its share price.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 9:06 pm

Benzinga Insights has identified five value stocks in the healthcare sector based on low P/E multiples, indicating potential undervaluation. The stocks include Cross Country Healthcare (CCRN), Akerna (KERN), Viatris (VTRS), Quoin Pharmaceuticals (QNRX), and Adial Pharmaceuticals (ADIL). CCRN reported a decrease in Q3 EPS, KERN reported a negative EPS that worsened from Q1, VTRS reported an increase in EPS and a decrease in dividend yield, QNRX showed an improvement in its negative EPS, and ADIL also improved its negative EPS.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 2:44 pm

US stocks traded lower with the Nasdaq Composite falling over 150 points. Autoliv Inc (NYSE:ALV) shares gained more than 7% after the company increased its annual sales forecast. Knight-Swift Transportation Holdings Inc. (NYSE:KNX), Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), and American Well Corporation (NYSE:AMWL) shares also rose. SolarEdge Technologies, Inc. (NASDAQ:SEDG), Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), and Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) shares fell.

Portfolio Pulse from Lisa Levin

October 20, 2023 | 6:42 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.